Articles Referencing PFS
Amgen's Oncology Drug Meets Primary Endpoint - Analyst Blog
6/13/2013, 6:29 pm from Zacks.com in Investing, Business, Stocks
Amgen ( AMGN ) recently
presented data on its late-stage oncology candidate, trebananib.
Results from the phase III global, multicenter, randomized,
double-blind, placebo-controlled... Read >>
CRL for AVEO/ALPMY's Tivozanib - Analyst Blog
6/12/2013, 7:29 pm from Zacks.com in Investing, Business, Stocks
AVEO Pharmaceuticals, Inc. ( AVEO ) and
Astellas Pharma, Inc. ( ALPMY ) recently
received a complete response letter (CRL) for tivozanib from the US
Food and Drug Administration (FDA). ... Read >>
Positive Data on Novartis' Afinitor - Analyst Blog
6/7/2013, 6:28 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced positive results on Afinitor, from a phase III trial,
BOLERO-3 (Breast cancer trials of OraL EveROlimus-3). The study evaluated Novartis' Afinitor plus
... Read >>
Positive Data on Bayer/Onyx's Nexavar - Analyst Blog
6/3/2013, 7:25 pm from Zacks.com in Investing, Business, Stocks
The HealthCare segment of Bayer ( BAYRY ) and partner,
Onyx Pharmaceuticals Inc. ( ONXX ) recently
announced positive results from the phase III DECISION study on
Nexavar (sorafenib)... Read >>
Roche Presents Data on Avastin - Analyst Blog
6/3/2013, 4:29 pm from Zacks.com in Investing, Business, Stocks
Roche ( RHHBY ) recently
announced positive results on oncology drug Avastin from a phase
III study, GOG240 (n=452). Results showed that Avastin, when added to chemotherapy
(paclitaxel and... Read >>
Oncogenex to Advance OGX-427 Development - Analyst Blog
5/24/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks
OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently
announced that it is looking to move its oncology candidate,
OGX-427, into a phase II study (Cedar: n~140). The study will
evaluate OGX-427... Read >>
Insider Trends in the Financial Services Sector
5/23/2013, 6:25 pm from GuruFocus in Investing
Over the past seven days, 73 separate insider buys have been
reported in 42 different financial services companies. These
companies reported that their insiders bought a minimum of 100
company... Read >>
Positive Data on Novartis' Afinitor - Analyst Blog
5/21/2013, 6:26 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced positive results on Afinitor, from a phase III trial,
BOLERO-3. The study is evaluating Novartis' Afinitor plus
Roche's ( RHHBY ) Herceptin... Read >>
Kinross Starting Feasibility Study on Tasiast Expansion (revised) - Analyst Blog
5/8/2013, 12:22 pm from Zacks.com in Investing, Business, Stocks
Kinross Gold Corporation ( KGC ) recently said
that it is moving ahead with a full feasibility study (FS) for a
possible expansion of its Tasiast mine in Mauritania with a 38,000
ton per... Read >>
Kinross Steps Up Tasiast Mine Expansion - Analyst Blog
5/6/2013, 12:40 pm from Zacks.com in Investing, Business, Stocks
Kinross Gold Corporation ( KGC ) announced that it
is moving ahead with its plans to further expand its Tasiast
project in Mauritania with a full feasibility study (FS) for a
38,000 ton... Read >>
Negative Opinion on AVEO/ALPMY Candidate - Analyst Blog
5/3/2013, 5:30 pm from Zacks.com in Investing, Business, Stocks
AVEO Pharmaceuticals Inc. ( AVEO ) and partner
Astellas Pharma, Inc. ( ALPMY ) recently
received disappointing news from the US Food and Drug
Administration (FDA) as its Oncologic Drugs... Read >>
PCYC Completes RESONATE Enrollment - Analyst Blog
4/19/2013, 3:30 pm from Zacks.com in Investing, Business, Stocks
Pharmacyclics, Inc. ( PCYC ) recently announced the completion of enrollment
in its phase III study RESONATE, which is being conducted to
evaluate ibrutinib versus Arzerra (ofatumumab)... Read >>
ImmunoGen to Focus on Pipeline - Analyst Blog
4/15/2013, 7:05 pm from Zacks.com in Investing, Business, Stocks
ImmunoGen Inc. ( IMGN ) recently
provided an update on its pipeline and maintained its outlook for
fiscal year 2013 (ending June 30) at its recently held Analyst
& Investor Day. ... Read >>
OncoGenex' OGX-427 Progresses - Analyst Blog
4/12/2013, 5:08 pm from Zacks.com in Investing, Business, Stocks
OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently
announced that it is looking to move its oncology candidate,
OGX-427, into a phase II study, Spruce, for the potential treatment
of... Read >>
Astellas/MDVN Provide Update on Xtandi - Analyst Blog
4/2/2013, 5:24 pm from Zacks.com in Investing, Business, Stocks
Astellas Pharma Inc. ( ALPMY ) and partner
Medivation, Inc. ( MDVN ) recently
announced that the companies have established an updated interim
analysis plan for an ongoing phase III... Read >>